- Home
- ARVN vs ADUS Comparison
ARVN vs ADUS Comparison
Compare ARVN & ADUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- ADUS
- Stock Information
- Founded
- ARVN 2015
- ADUS 1979
- Country
- ARVN United States
- ADUS United States
- Employees
- ARVN N/A
- ADUS N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- ADUS Medical/Nursing Services
- Sector
- ARVN Health Care
- ADUS Health Care
- Exchange
- ARVN Nasdaq
- ADUS Nasdaq
- Market Cap
- ARVN 1.7B
- ADUS 2.0B
- IPO Year
- ARVN 2018
- ADUS 2009
- Fundamental
- Price
- ARVN $27.04
- ADUS $133.01
- Analyst Decision
- ARVN Strong Buy
- ADUS Buy
- Analyst Count
- ARVN 15
- ADUS 9
- Target Price
- ARVN $57.50
- ADUS $131.63
- AVG Volume (30 Days)
- ARVN 562.1K
- ADUS 120.8K
- Earning Date
- ARVN 11-05-2024
- ADUS 10-28-2024
- Dividend Yield
- ARVN N/A
- ADUS N/A
- EPS Growth
- ARVN N/A
- ADUS 26.93
- EPS
- ARVN N/A
- ADUS 4.20
- Revenue
- ARVN $93,300,000.00
- ADUS $1,114,740,000.00
- Revenue This Year
- ARVN $179.49
- ADUS $11.37
- Revenue Next Year
- ARVN N/A
- ADUS $14.93
- P/E Ratio
- ARVN N/A
- ADUS $31.67
- Revenue Growth
- ARVN N/A
- ADUS 11.57
- 52 Week Low
- ARVN $13.57
- ADUS $78.35
- 52 Week High
- ARVN $53.08
- ADUS $136.12
- Technical
- Relative Strength Index (RSI)
- ARVN 59.76
- ADUS 57.70
- Support Level
- ARVN $25.42
- ADUS $126.16
- Resistance Level
- ARVN $29.24
- ADUS $134.32
- Average True Range (ATR)
- ARVN 1.21
- ADUS 2.95
- MACD
- ARVN 0.29
- ADUS 0.39
- Stochastic Oscillator
- ARVN 58.72
- ADUS 86.74
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.